FiercePharma1d
Astellas' eye med Izervay lands key FDA label update, amping up market battle with Apellis rival
In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med ...
Managed Healthcare Executive1d
FDA Approves Expanded Label for Izervay, No Dosing Duration Limit
The updated label allows physicians to prescribe Izervay without a limitation on duration for patients with geographic ...
The Pharma Letter1d
Wider label approved for Izervay by FDA
The US Food and Drug Administration (FDA) approved expanding the prescribing information for Japanese drugmaker Astellas ...
pharmaphorum2d
FDA changes its mind on Astellas' geographic atrophy drug
Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will ...
U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAY™ ...
Pharmabiz1d
US FDA approves expanded label for Astellas’ Izervay for the treatment of geographic atrophy
US FDA approves expanded label for Astellas’ Izervay for the treatment of geographic atrophy: Tokyo Friday, February 14, 2025, 09:00 Hrs [IST] Astellas Pharma Inc., a global lif ...
Monthly Prescribing Reference1d
Izervay Label Update Removes Limit on Treatment Duration for Geographic Atrophy
The Food and Drug Administration (FDA) has expanded the labeling for Izervay™ (avacincaptad pegol intravitreal solution) to include longer-term ...
FiercePharma22h
Fierce Pharma Asia—Astellas' investment focus; Mitsubishi Tanabe's buyout; Leqembi's 'expansion phase'
Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...
U.S. FDA Approves Expanded Label For Astellas' IZERVAYTM (Avacincaptad Pegol Intravitreal Solution) For Geographic Atrophy
IZERVAY dosing approved beyond 12 monthsTOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Ok ...
Medpage Today on MSN1d
Top NIH Official Forced Out; Trump Sued by Fired HHS Watchdog; E. Coli Vaccine Flops
The FDA approved brentuximab vedotin (Adcetris) in combination with lenalidomide (Revlimid) and rituximab for relapsed or ...
MM&M1d
Rx Rundown: Novartis, Abcuro, SpringWorks Therapeutics and more
RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...